RIMACTANE Side Effects

5716169-2 | Bovine Tuberculosis, Bronchial Hyperreactivity, Cholestasis, Condition Aggravated, Cytolytic Hepatitis, Liver Injury, Lung Neoplasm, Sepsis
on Apr 10, 2008 Female patient from SWITZERLAND , 55 years of age, weighting 176.4 lb, was diagnosed with bladder cancer (What is bladder cancer?), urinary tract infection (What is urinary tract infection?) and was treated with Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: bovine tuberculosis, bronchial hyperreactivity, cholestasis, condition aggravated, cytolytic hepatitis, liver injury, lung neoplasm, sepsis (What is sepsis?). Rimactane dosage: 600 Mg, Qd, Oral. During the same period patient was treated with IMMUCYST (81 Mg, Qw, Urethral) (View Immucyst Review and Immucyst Label ), ROCEPHIN (1 Df, Qd, Iv Drip) (View Rocephin Review and Rocephin Label ), RIMIFON (300 Mg, Qd, Oral) (View Rimifon Review and Rimifon Label ), SIMCORA (SIMVASTATIN) (View Simcora (simvastatin) Review and Simcora (simvastatin) Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ). Patient was hospitalized.

5638384-9 | Encephalopathy, Feeling Abnormal, Gait Disturbance, Hallucination, Motor Dysfunction, Speech Disorder
Patient was taking Rimactane (View Usage). Patient had the following side effects: encephalopathy, feeling abnormal, gait disturbance, hallucination, motor dysfunction, speech disorder on Feb 14, 2008 from SWEDEN Additional patient health information: Male patient , 82 years of age, was diagnosed with infection (What is infection?), pain in extremity and. Rimactane dosage: 600 Mg, Oral. During the same period patient was treated with CLINDAMYCIN (CLINDAMYCIN) HARD GELATIN GAPSULE (View Clindamycin (clindamycin) Hard-gelatin Gapsule Review and Clindamycin (clindamycin) Hard-gelatin Gapsule Label ), RAMIPRIL (View Ramipril Review and Ramipril Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), LEVOMEPROMAZINE MALEATE (LEVOMEPROMAZINE MALEATE) TABLET (View Levomepromazine Maleate (levomepromazine Maleate) Tablet Review and Levomepromazine Maleate (levomepromazine Maleate) Tablet Label ), FUROSEMIDE (View Furosemide Review and Furosemide Label ), BISOPROLOL HEMIFUMARATE (BISOPROLOL HEMIFUMARATE) FILM COATED TABLET (View Bisoprolol Hemifumarate (bisoprolol Hemifumarate) Film-coated Tablet Review and Bisoprolol Hemifumarate (bisoprolol Hemifumarate) Film-coated Tablet Label ), ACETYLSALICYLIC ACID (ACETYLSALICYLIC ACID) TABLET (View Acetylsalicylic Acid (acetylsalicylic Acid) Tablet Review and Acetylsalicylic Acid (acetylsalicylic Acid) Tablet Label ). Patient was hospitalized.

5352274-0 | Herpes Zoster Disseminated, Immune Reconstitution Syndrome
Adverse event was reported on Jun 06, 2007 by a Male patient taking Rimactane (View Usage) (Dosage: Dose: Unk) was diagnosed with pulmonary tuberculosis and. Location: JAPAN , 58 years of age, After Rimactane was administered, patient had the following side effects: herpes zoster disseminated, immune reconstitution syndrome. During the same period patient was treated with PYRAMIDE (Dose: Unk) (View Pyramide Review and Pyramide Label ), ISCOTIN /00030201/ (Dose: Unk) (View Iscotin /00030201/ Review and Iscotin /00030201/ Label ), STREPTOMYCIN (Dose: Unk) (View Streptomycin Review and Streptomycin Label ), ETHAMBUTOL HYDROCHLORIDE (Dose: Unk) (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ).

5259057-0 | Blood Glucose Decreased, Blood Pressure Decreased, Cardio-respiratory Arrest, Condition Aggravated, Disseminated Intravascular Coagulation, Haemolytic Anaemia, Hepatitis Fulminant, Loss Of Consciousness, Melaena
on Feb 21, 2007 Female patient from JAPAN , 75 years of age, weighting 72.75 lb, was diagnosed with mycobacterial infection and was treated with Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: blood glucose decreased, blood pressure decreased, cardio-respiratory arrest, condition aggravated, disseminated intravascular coagulation, haemolytic anaemia, hepatitis fulminant, loss of consciousness, melaena. Rimactane dosage: 450 Mg, Oral. During the same period patient was treated with ETHAMBUTOL HYDROCHLORIDE (750 Mg, Oral) (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ), CLARITHROMYCIN (View Clarithromycin Review and Clarithromycin Label ), MUCODYNE (CARBOCISTEINE) (View Mucodyne (carbocisteine) Review and Mucodyne (carbocisteine) Label ), GLORIAMIN (AZULENE SODIUM SULFONATE, LEVOGLUTAMIDE) (View Gloriamin (azulene Sodium Sulfonate, Levoglutamide) Review and Gloriamin (azulene Sodium Sulfonate, Levoglutamide) Label ), PURSENNID (SENNOSIDE A+B, SENNOSIDE A+B CALCIUM) (View Pursennid (sennoside A+b, Sennoside A+b Calcium) Review and Pursennid (sennoside A+b, Sennoside A+b Calcium) Label ), KAMAG G (MAGNESIUM OXIDE) (View Kamag G (magnesium Oxide) Review and Kamag G (magnesium Oxide) Label ), JUZENTAIHOTO (HEREBAL EXTRACT NOS, HERBAL EXTRACTS NOS) (View Juzentaihoto (herebal Extract Nos, Herbal Extracts Nos) Review and Juzentaihoto (herebal Extract Nos, Herbal Extracts Nos) Label ), UNASYN (SULTAMICILLIN TOSILATE) (View Unasyn (sultamicillin Tosilate) Review and Unasyn (sultamicillin Tosilate) Label ). Patient was hospitalized.


5246240-3 | Dysuria, Haematuria, Urine Analysis Abnormal
on Feb 08, 2007 Male patient from JAPAN , 80 years of age, was diagnosed with tuberculosis (What is tuberculosis?) and was treated with Rimactane (View Usage). Patient had the following side effects: dysuria, haematuria, urine analysis abnormal. Rimactane dosage: 450 Mg, Oral. During the same period patient was treated with ETHAMBUTOL HCL (View Ethambutol Hcl Review and Ethambutol Hcl Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ), DEPAS (ETIZOLAM) (View Depas (etizolam) Review and Depas (etizolam) Label ), ROHYPNOL (FLUNITRAZEPAM) (View Rohypnol (flunitrazepam) Review and Rohypnol (flunitrazepam) Label ), ENSURE (AMINO ACIDS NOS, MINERALS NOS, VITAMINS NOS) (View Ensure (amino Acids Nos, Minerals Nos, Vitamins Nos) Review and Ensure (amino Acids Nos, Minerals Nos, Vitamins Nos) Label ), AVISHOT (NAFTOPIDIL) (View Avishot (naftopidil) Review and Avishot (naftopidil) Label ), LANIRAPID (METILDIGOXIN) (View Lanirapid (metildigoxin) Review and Lanirapid (metildigoxin) Label ).

5148158-3 | Acid Fast Bacilli Infection, Angina Unstable, Blood Glucose Decreased, Blood Pressure Decreased, Cardio-respiratory Arrest, Condition Aggravated, Continuous Haemodiafiltration, Disseminated Intravascular Coagulation, Dyspnoea
Patient was taking Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: acid fast bacilli infection, angina unstable, blood glucose decreased, blood pressure decreased, cardio-respiratory arrest, condition aggravated, continuous haemodiafiltration, disseminated intravascular coagulation, dyspnoea on Oct 26, 2006 from JAPAN Additional patient health information: Female patient , 75 years of age, weighting 72.75 lb, was diagnosed with mycobacterial infection and. Rimactane dosage: 450 Mg, Oral. During the same period patient was treated with ETHAMBUTOL HCL (750 Mg, Oral) (View Ethambutol Hcl Review and Ethambutol Hcl Label ), CLARITHROMYCIN (View Clarithromycin Review and Clarithromycin Label ), MUCODYNE (CARBOCISTEINE) (View Mucodyne (carbocisteine) Review and Mucodyne (carbocisteine) Label ), GLORIAMIN (AZULENE SODIUM SULFONATE, LEVOGLUTAMIDE) (View Gloriamin (azulene Sodium Sulfonate, Levoglutamide) Review and Gloriamin (azulene Sodium Sulfonate, Levoglutamide) Label ), PURSENNID (SENNOSIDE A+B, SENNOSIDE A+B CALCIUM) (View Pursennid (sennoside A+b, Sennoside A+b Calcium) Review and Pursennid (sennoside A+b, Sennoside A+b Calcium) Label ), KAMAG G (MAGNESIUM OXIDE) (View Kamag G (magnesium Oxide) Review and Kamag G (magnesium Oxide) Label ), JUZENTAIHOTO (HERBAL EXTRACT NOS, HERBAL EXTRACTS NOS) (View Juzentaihoto (herbal Extract Nos, Herbal Extracts Nos) Review and Juzentaihoto (herbal Extract Nos, Herbal Extracts Nos) Label ), UNASYN (SULTAMICILLIN TOSILATE) (View Unasyn (sultamicillin Tosilate) Review and Unasyn (sultamicillin Tosilate) Label ). Patient was hospitalized.

5132673-2 | Abdominal Pain Upper, Blood Alkaline Phosphatase Decreased, Blood Bilirubin Abnormal, Blood Glucose Decreased, Blood Sodium Decreased, Cyanosis, Discomfort, Fatigue
Adverse event was reported on Oct 05, 2006 by a Female patient taking Rimactane (View Usage) (Dosage: 1 Tablet, Qd, Oral) was diagnosed with leprosy and. Location: BRAZIL , 37 years of age, weighting 138.9 lb, Patient experienced the following unwanted or unexpected effects: abdominal pain upper, blood alkaline phosphatase decreased, blood bilirubin abnormal, blood glucose decreased, blood sodium decreased, cyanosis, discomfort, fatigue. During the same period patient was treated with DAPSONE (1 Tablet, Qd, Oral) (View Dapsone Review and Dapsone Label ), CLOFAZIMINE (CLOFAZIMINE) (Oral) (View Clofazimine (clofazimine) Review and Clofazimine (clofazimine) Label ).

5127676-8 | Abdominal Pain Upper, Blood Alkaline Phosphatase Decreased, Blood Bilirubin Abnormal, Blood Glucose Decreased, Blood Sodium Decreased, Cyanosis, Discomfort, Fatigue
on Jul 31, 2006 Female patient from BRAZIL , 37 years of age, weighting 138.9 lb, was diagnosed with leprosy and was treated with Rimactane (View Usage). Patient had the following side effects: abdominal pain upper, blood alkaline phosphatase decreased, blood bilirubin abnormal, blood glucose decreased, blood sodium decreased, cyanosis, discomfort, fatigue. Rimactane dosage: 1 Tablet, Qd. During the same period patient was treated with DAPSONE (Unk, Unk) (View Dapsone Review and Dapsone Label ), CLOFAZIMINE (View Clofazimine Review and Clofazimine Label ).

5120497-1 | Blood Albumin Decreased, Glomerulonephritis Minimal Lesion, Headache, Nephrotic Syndrome, Renal Failure Acute, Tubulointerstitial Nephritis
on Sep 21, 2006 Male patient from JAPAN , 72 years of age, was diagnosed with tuberculous pleurisy and was treated with Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: blood albumin decreased, glomerulonephritis minimal lesion, headache (What is headache?), nephrotic syndrome, renal failure acute, tubulointerstitial nephritis. Rimactane dosage: Oral. During the same period patient was treated with PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ), ETHAMBUTOL (NGX) (ETHAMBUTOL) (View Ethambutol (ngx) (ethambutol) Review and Ethambutol (ngx) (ethambutol) Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ). Patient was hospitalized.

5115350-3 | Hypoalbuminaemia, Nephritis Interstitial, Nephrotic Syndrome, Proteinuria, Renal Failure Acute
Patient was taking Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: hypoalbuminaemia, nephritis interstitial, nephrotic syndrome, proteinuria, renal failure acute on Sep 13, 2006 from JAPAN Additional patient health information: Male patient , 72 years of age, was diagnosed with tuberculous pleurisy and. Rimactane dosage: Oral. During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), ETHAMBUTOL HYDROCHLORIDE (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ). Patient was hospitalized.

5067242-6 | Nephritis Interstitial, Nephrotic Syndrome, Renal Failure Acute
Adverse event was reported on Jul 12, 2006 by a Male patient taking Rimactane (View Usage) (Dosage: Oral) was diagnosed with tuberculous pleurisy and. Location: JAPAN , 72 years of age, Patient had the following side effects: nephritis interstitial, nephrotic syndrome, renal failure acute. During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), ETHAMBUTOL (ETHAMBUTOL) (View Ethambutol (ethambutol) Review and Ethambutol (ethambutol) Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ). Patient was hospitalized.

5067241-4 | Blood Albumin Decreased, Blood Creatinine Increased, Blood Urea Increased, Hypoalbuminaemia, Nephritis Interstitial, Nephrotic Syndrome, Proteinuria, Renal Failure Acute
on Jul 12, 2006 Male patient from JAPAN , 72 years of age, was diagnosed with tuberculous pleurisy and was treated with Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: blood albumin decreased, blood creatinine increased, blood urea increased, hypoalbuminaemia, nephritis interstitial, nephrotic syndrome, proteinuria, renal failure acute. Rimactane dosage: Oral. During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), ETHAMBUTOL (ETHAMBUTOL) (View Ethambutol (ethambutol) Review and Ethambutol (ethambutol) Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ). Patient was hospitalized.

5050825-7 | Haemodialysis, Hepatic Failure, Hepatitis Fulminant, Somnolence, White Blood Cell Count Decreased
on Jun 27, 2006 Male patient from JAPAN , 66 years of age, was diagnosed with pulmonary tuberculosis and was treated with Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: haemodialysis, hepatic failure, hepatitis fulminant, somnolence, white blood cell count decreased. Rimactane dosage: 300 Mg, Oral. During the same period patient was treated with ISONIAZID (400 Mg, Oral) (View Isoniazid Review and Isoniazid Label ), PYRAZINAMIDE (1 G, Oral) (View Pyrazinamide Review and Pyrazinamide Label ), ETHAMBUTOL HCL (500 Mg, Oral) (View Ethambutol Hcl Review and Ethambutol Hcl Label ), ADEROXAL (PYRIDOXAL PHOSPHATE) (View Aderoxal (pyridoxal Phosphate) Review and Aderoxal (pyridoxal Phosphate) Label ).

5031340-3 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Creatinine Increased
Patient was taking Rimactane (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood creatinine increased on Jun 07, 2006 from SWEDEN Additional patient health information: Female patient , 76 years of age, . Rimactane dosage: 600 Mg, Oral. During the same period patient was treated with HERACILLIN (FLUCLOXACILLIN SODIUM) 500MG (Oral) (View Heracillin (flucloxacillin Sodium) 500mg Review and Heracillin (flucloxacillin Sodium) 500mg Label ), SELOKEN ZOC (METOPROLOL SUCCINATE) (View Seloken Zoc (metoprolol Succinate) Review and Seloken Zoc (metoprolol Succinate) Label ), HALDOL (View Haldol Review and Haldol Label ), IMURAN (View Imuran Review and Imuran Label ), DUROFERON (FERROUS SULFATE) (View Duroferon (ferrous Sulfate) Review and Duroferon (ferrous Sulfate) Label ), PREDNISOLON PFIZER (PREDNISOLONE) (View Prednisolon Pfizer (prednisolone) Review and Prednisolon Pfizer (prednisolone) Label ), LASIX (View Lasix Review and Lasix Label ), ALVEDON (PARACETAMOL) (View Alvedon (paracetamol) Review and Alvedon (paracetamol) Label ).

5003895-6 | Cholestasis, Condition Aggravated, Haemolytic Anaemia, Inflammation, Liver Disorder
Adverse event was reported on May 02, 2006 by a Female patient taking Rimactane (View Usage) (Dosage: See Image) was diagnosed with sepsis (What is sepsis?) and. Location: FRANCE , 62 years of age, After Rimactane was administered, patient had the following side effects: cholestasis, condition aggravated, haemolytic anaemia, inflammation, liver disorder. During the same period patient was treated with CIPROFLOXACIN (2 Df, Oral) (View Ciprofloxacin Review and Ciprofloxacin Label ), PRIMAXIN (View Primaxin Review and Primaxin Label ), VITAMIN B1 TAB (View Vitamin B1 Tab Review and Vitamin B1 Tab Label ), INEXIUM (ESOMEPRAZOLE) (View Inexium (esomeprazole) Review and Inexium (esomeprazole) Label ), SPECIAFOLDINE (FOLIC ACID) (View Speciafoldine (folic Acid) Review and Speciafoldine (folic Acid) Label ), FERROUS SULFATE TAB (View Ferrous Sulfate Tab Review and Ferrous Sulfate Tab Label ). Patient was hospitalized.

4999319-5 | Arthralgia
on Mar 31, 2006 Female patient from SWITZERLAND , 44 years of age, weighting 97.00 lb, was diagnosed with tuberculosis (What is tuberculosis?), systemic lupus erythematosus and was treated with Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: arthralgia. Rimactane dosage: . During the same period patient was treated with CELLCEPT (View Cellcept Review and Cellcept Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), FOSAMAX (View Fosamax Review and Fosamax Label ). Patient was hospitalized.

4998628-3 | Coma Hepatic, Hepatic Cirrhosis, Nausea
on Apr 27, 2006 Female patient from GREENLAND , 66 years of age, weighting 121.3 lb, was diagnosed with tuberculosis (What is tuberculosis?) and was treated with Rimactane (View Usage). Patient had the following side effects: coma hepatic, hepatic cirrhosis, nausea (What is nausea?). Rimactane dosage: 2 Gm, Oral. During the same period patient was treated with ISONIAZID 'OBA' (ISONIAZID) (300 Mg, Oral) (View Isoniazid 'oba' (isoniazid) Review and Isoniazid 'oba' (isoniazid) Label ), MYAMBUTOL (View Myambutol Review and Myambutol Label ), PRIMPERAN TAB (View Primperan Tab Review and Primperan Tab Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ). Patient was hospitalized.

4958152-0 | Anorexia, Bronchopulmonary Aspergillosis, Hepatic Function Abnormal, Pulmonary Necrosis
Patient was taking Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: anorexia, bronchopulmonary aspergillosis, hepatic function abnormal, pulmonary necrosis on Mar 14, 2006 from JAPAN Additional patient health information: Male patient , 76 years of age, weighting 77.60 lb, was diagnosed with pulmonary tuberculosis and. Rimactane dosage: . During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), ETHAMBUTOL (ETHAMBUTOL) (View Ethambutol (ethambutol) Review and Ethambutol (ethambutol) Label ). Patient was hospitalized.

4956298-4 | Bronchopulmonary Aspergillosis
Adverse event was reported on Mar 08, 2006 by a Male patient taking Rimactane (View Usage) (Dosage: ) . Location: JAPAN , 76 years of age, Patient experienced the following unwanted or unexpected effects: bronchopulmonary aspergillosis. Patient was hospitalized.

4906060-3 | Bronchopulmonary Aspergillosis, Haemoptysis, Hepatic Function Abnormal, Malnutrition, Respiratory Failure, Shock
on Jan 25, 2006 Male patient from JAPAN , 70 years of age, was diagnosed with pulmonary tuberculosis and was treated with Rimactane (View Usage). Patient had the following side effects: bronchopulmonary aspergillosis, haemoptysis, hepatic function abnormal, malnutrition, respiratory failure, shock. Rimactane dosage: . During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), STREPTOMYCIN (View Streptomycin Review and Streptomycin Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ). Patient was hospitalized.

4848790-8 | Nephritis Interstitial
on Nov 24, 2005 Female patient from JAPAN , 68 years of age, was diagnosed with pulmonary tuberculosis and was treated with Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: nephritis interstitial. Rimactane dosage: Oral. During the same period patient was treated with ISONIAZID (Oral) (View Isoniazid Review and Isoniazid Label ), PYRAZINAMIDE (Oral) (View Pyrazinamide Review and Pyrazinamide Label ), ESANBUTOL (ETHAMBUTOL) (Oral) (View Esanbutol (ethambutol) Review and Esanbutol (ethambutol) Label ).

4843842-0 | Autoimmune Thyroiditis, Hypothyroidism
Patient was taking Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: autoimmune thyroiditis, hypothyroidism on Nov 16, 2005 from JAPAN Additional patient health information: Male patient , 62 years of age, was diagnosed with tuberculosis (What is tuberculosis?) and. Rimactane dosage: Oral.

4842880-1 | Hepatitis, Histiocytosis Haematophagic
Adverse event was reported on Nov 16, 2005 by a Male patient taking Rimactane (View Usage) (Dosage: Oral) was diagnosed with pulmonary tuberculosis and. Location: JAPAN , 79 years of age, Patient had the following side effects: hepatitis (What is hepatitis?), histiocytosis haematophagic. During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ), ETHAMBUTOL HCL (View Ethambutol Hcl Review and Ethambutol Hcl Label ).

4842879-5 | Autoimmune Thyroiditis, Hypothyroidism
on Nov 16, 2005 Female patient from JAPAN , 56 years of age, was diagnosed with tuberculosis (What is tuberculosis?) and was treated with Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: autoimmune thyroiditis, hypothyroidism. Rimactane dosage: Oral.

4842878-3 | Autoimmune Thyroiditis, Hypothyroidism
on Nov 16, 2005 Female patient from JAPAN , 66 years of age, was diagnosed with peritoneal tuberculosis and was treated with Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: autoimmune thyroiditis, hypothyroidism. Rimactane dosage: Oral.

4831990-0 | Haematuria, Haemodialysis, Nephritis Interstitial, Renal Failure Acute
Patient was taking Rimactane (View Usage). Patient had the following side effects: haematuria, haemodialysis, nephritis interstitial, renal failure acute on Oct 12, 2005 from JAPAN Additional patient health information: Male patient , 72 years of age, weighting 112.4 lb, was diagnosed with pulmonary tuberculosis and. Rimactane dosage: Oral. During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), STREPTOMYCIN SULFATE (STREPTOMYCIN SULFATE) (View Streptomycin Sulfate (streptomycin Sulfate) Review and Streptomycin Sulfate (streptomycin Sulfate) Label ), ETHAMBUTOL HCL (View Ethambutol Hcl Review and Ethambutol Hcl Label ). Patient was hospitalized.

4811423-0 | Condition Aggravated, Finger Amputation, Inflammation, Intestinal Ulcer Perforation, Mycobacterium Chelonei Infection, Nodule On Extremity, Osteomyelitis, Paronychia, Rash
Adverse event was reported on Sep 28, 2005 by a Female patient taking Rimactane (View Usage) (Dosage: 450 Mg/d) was diagnosed with mycobacterium chelonei infection, systemic sclerosis, nephrotic syndrome, paronychia and. Location: JAPAN , 67 years of age, After Rimactane was administered, patient had the following side effects: condition aggravated, finger amputation, inflammation, intestinal ulcer perforation, mycobacterium chelonei infection, nodule on extremity, osteomyelitis, paronychia, rash (What is rash?). During the same period patient was treated with MEDROL (10 Mg/d) (View Medrol Review and Medrol Label ), NEORAL (50 Mg/d) (View Neoral Review and Neoral Label ), MINOCYCLINE (View Minocycline Review and Minocycline Label ), CLARITHROMYCIN (800 Mg/d) (View Clarithromycin Review and Clarithromycin Label ), KANAMYCIN SULFATE (1800 Mg/d) (View Kanamycin Sulfate Review and Kanamycin Sulfate Label ), ERYTHROMYCIN (1000 Mg/d) (View Erythromycin Review and Erythromycin Label ), LEVOFLOXACIN (300 Mg/d) (View Levofloxacin Review and Levofloxacin Label ), ISONIAZID (300 Mg/d) (View Isoniazid Review and Isoniazid Label ). Patient was hospitalized.

4803658-8 | Ventricular Tachycardia
on Oct 05, 2005 Male patient from JAPAN , 69 years of age, was diagnosed with pulmonary tuberculosis, ventricular tachycardia and was treated with Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: ventricular tachycardia. Rimactane dosage: Oral. During the same period patient was treated with AMIODARONE HCL (View Amiodarone Hcl Review and Amiodarone Hcl Label ).

4751145-8 | Nephrotic Syndrome, Renal Failure Acute, Tubulointerstitial Nephritis
on Aug 10, 2005 Male patient from JAPAN , 72 years of age, was diagnosed with tuberculous pleurisy and was treated with Rimactane (View Usage). Patient had the following side effects: nephrotic syndrome, renal failure acute, tubulointerstitial nephritis. Rimactane dosage: Oral. During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), ETHAMBUTOL HYDROCHLORIDE (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ). Patient was hospitalized.

4710998-X | Chills, Leukopenia, Neutropenia, Pyrexia, Rash Erythematous, Rash Macular
Patient was taking Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: chills, leukopenia, neutropenia, pyrexia, rash erythematous, rash macular on Jun 27, 2005 from FRANCE Additional patient health information: Male patient , 54 years of age, was diagnosed with staphylococcal infection (What is staphylococcal infection?) and. Rimactane dosage: Oral. During the same period patient was treated with RIFAMPICIN (Intravenous) (View Rifampicin Review and Rifampicin Label ), BACTRIM (View Bactrim Review and Bactrim Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ), FUCIDINE CAP (View Fucidine Cap Review and Fucidine Cap Label ). Patient was hospitalized.

4705671-8 | Nephrotic Syndrome, Renal Failure Acute
Adverse event was reported on Jun 15, 2005 by a Female patient taking Rimactane (View Usage) (Dosage: Oral) was diagnosed with tuberculous pleurisy and. Location: , 46 years of age, Patient experienced the following unwanted or unexpected effects: nephrotic syndrome, renal failure acute. During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ), ESANBUTOL (ETHAMBUTOL) (View Esanbutol (ethambutol) Review and Esanbutol (ethambutol) Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

4699422-3 | Cytolytic Hepatitis, Haemoglobin Decreased, Hepatitis Cholestatic, Lymphopenia, Platelet Count Increased
on Jun 10, 2005 Male patient from , 87 years of age, was diagnosed with streptococcal infection (What is streptococcal infection?) and was treated with Rimactane (View Usage). Patient had the following side effects: cytolytic hepatitis, haemoglobin decreased, hepatitis cholestatic, lymphopenia, platelet count increased. Rimactane dosage: 1800 Mg, Qd, Oral. During the same period patient was treated with CLAMOXYL (AMOXICILLIN TRHIHYDRATE) (8 G, Qd, Oral) (View Clamoxyl (amoxicillin Trhihydrate) Review and Clamoxyl (amoxicillin Trhihydrate) Label ), OMEPRAZOLE (40 Mg, Qd, Oral) (View Omeprazole Review and Omeprazole Label ), GLYBURIDE (2.5 Mg, Qd; Oral) (View Glyburide Review and Glyburide Label ), ACETAMINOPHEN (3 G, Qd, Oral) (View Acetaminophen Review and Acetaminophen Label ), OMIX (TAMSULOSIN HYDROCHLORIDE) (0.4 Mg , Qd, Oral) (View Omix (tamsulosin Hydrochloride) Review and Omix (tamsulosin Hydrochloride) Label ). Patient was hospitalized.

4697886-2 | Optic Neuropathy
on Jun 08, 2005 Female patient from , 59 years of age, was diagnosed with pulmonary tuberculosis and was treated with Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: optic neuropathy. Rimactane dosage: Oral. During the same period patient was treated with ISONIAZID (Oral) (View Isoniazid Review and Isoniazid Label ), ESANBUTOL (ETHAMBUTOL) (Oral) (View Esanbutol (ethambutol) Review and Esanbutol (ethambutol) Label ).

4697879-5 | Disease Progression, Disseminated Tuberculosis, Respiratory Failure
Patient was taking Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: disease progression, disseminated tuberculosis, respiratory failure on Jun 08, 2005 from Additional patient health information: Male patient , 68 years of age, weighting 110.2 lb, was diagnosed with tuberculosis (What is tuberculosis?) and. Rimactane dosage: . During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ), ESANBUTOL (ETHAMBUTOL) (View Esanbutol (ethambutol) Review and Esanbutol (ethambutol) Label ), CEFTRIAXONE (View Ceftriaxone Review and Ceftriaxone Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ). Patient was hospitalized.

4692231-0 | Gastric Ulcer Perforation, Hepatocellular Damage, Liver Disorder, Multi-organ Failure, Oesophageal Perforation, Pneumomediastinum
Adverse event was reported on Jun 01, 2005 by a Male patient taking Rimactane (View Usage) (Dosage: ) was diagnosed with pleurisy and. Location: , 47 years of age, Patient had the following side effects: gastric ulcer perforation, hepatocellular damage, liver disorder, multi-organ failure, oesophageal perforation, pneumomediastinum. During the same period patient was treated with ETHAMBUTOL HCL (View Ethambutol Hcl Review and Ethambutol Hcl Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ), PYRAMIDE (PYRADMIDE) (View Pyramide (pyradmide) Review and Pyramide (pyradmide) Label ). Patient was hospitalized.

4657025-0 | Adrenocortical Insufficiency Acute
on Apr 28, 2005 Male patient from , 63 years of age, was diagnosed with pulmonary tuberculosis and was treated with Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: adrenocortical insufficiency acute. Rimactane dosage: Oral.

4649208-0 | Adrenocortical Insufficiency Acute
on Apr 06, 2005 Male patient from , 63 years of age, was diagnosed with pulmonary tuberculosis and was treated with Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: adrenocortical insufficiency acute. Rimactane dosage: Oral.

4647776-6 | Dyspnoea, Sepsis, Stevens-johnson Syndrome
Patient was taking Rimactane (View Usage). Patient had the following side effects: dyspnoea, sepsis (What is sepsis?), stevens-johnson syndrome on Apr 13, 2005 from Additional patient health information: Male patient , 56 years of age, was diagnosed with pulmonary tuberculosis and. Rimactane dosage: . During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), ESANBUTOL (ETHAMBUTOL) (View Esanbutol (ethambutol) Review and Esanbutol (ethambutol) Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ). Patient was hospitalized.

4639630-0 | Adrenocortical Insufficiency Acute
Adverse event was reported on Apr 06, 2005 by a Male patient taking Rimactane (View Usage) (Dosage: Oral) . Location: , 63 years of age, After Rimactane was administered, patient had the following side effects: adrenocortical insufficiency acute.

4629343-3 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Inflammation, Liver Disorder, Lymphocyte Stimulation Test Positive, Somnolence, Stevens-johnson Syndrome
on Mar 29, 2005 Male patient from , 69 years of age, was diagnosed with mycobacteria blood test positive and was treated with Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, inflammation, liver disorder, lymphocyte stimulation test positive, somnolence, stevens-johnson syndrome. Rimactane dosage: Oral. During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), PYRAZINAMIDE (Oral) (View Pyrazinamide Review and Pyrazinamide Label ). Patient was hospitalized.

4629341-X | Blood Glucose Increased, Glycosylated Haemoglobin Increased, Toxic Epidermal Necrolysis
on Mar 22, 2005 Male patient from , 70 years of age, weighting 110.2 lb, was diagnosed with mycobacteria blood test positive and was treated with Rimactane (View Usage). Patient had the following side effects: blood glucose increased, glycosylated haemoglobin increased, toxic epidermal necrolysis. Rimactane dosage: 450 Mg, Oral. During the same period patient was treated with ISONIAZID (300 Mg, Oral) (View Isoniazid Review and Isoniazid Label ), ESANBUTOL(ETHAMBUTOL) (750 Mg, Oral) (View Esanbutol(ethambutol) Review and Esanbutol(ethambutol) Label ), FUNGUARD (MICAFUNGUN SODIUM) (View Funguard (micafungun Sodium) Review and Funguard (micafungun Sodium) Label ), AMLODIPINE BESYLATE (View Amlodipine Besylate Review and Amlodipine Besylate Label ), NEUROTROPIN (ORGAN LYSATE, STANDARDIZED) (View Neurotropin (organ Lysate, Standardized) Review and Neurotropin (organ Lysate, Standardized) Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

4621018-X | Liver Disorder, Stevens-johnson Syndrome
Patient was taking Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: liver disorder, stevens-johnson syndrome on Mar 16, 2005 from Additional patient health information: Male patient , 69 years of age, was diagnosed with mycobacteria blood test positive and. Rimactane dosage: Oral. During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), ESANBUTOL(ETHAMBUTOL) (View Esanbutol(ethambutol) Review and Esanbutol(ethambutol) Label ).

4616190-1 | Toxic Epidermal Necrolysis
Adverse event was reported on Mar 07, 2005 by a Male patient taking Rimactane (View Usage) (Dosage: Oral) was diagnosed with tuberculosis (What is tuberculosis?) and. Location: , 70 years of age, Patient experienced the following unwanted or unexpected effects: toxic epidermal necrolysis. During the same period patient was treated with ISCONTIN (ISONIAZID) (View Iscontin (isoniazid) Review and Iscontin (isoniazid) Label ), ESANBUTOL (ETHAMBUTOL) (Oral) (View Esanbutol (ethambutol) Review and Esanbutol (ethambutol) Label ).

4586421-5 | Haemolytic Anaemia, Renal Impairment
on Feb 09, 2005 Female patient from , 37 years of age, was diagnosed with leprosy and was treated with Rimactane (View Usage). Patient had the following side effects: haemolytic anaemia, renal impairment. Rimactane dosage: . During the same period patient was treated with LAMPRENE (View Lamprene Review and Lamprene Label ), DIAPHENYLSULFON (View Diaphenylsulfon Review and Diaphenylsulfon Label ), LEVOFLOXACIN (View Levofloxacin Review and Levofloxacin Label ), CLARITHROMYCIN (View Clarithromycin Review and Clarithromycin Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

4573943-6 | Blood Creatinine Increased
on Jan 26, 2005 Male patient from , 34 years of age, was diagnosed with tuberculosis gastrointestinal and was treated with Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: blood creatinine increased. Rimactane dosage: 300 Mg, Oral. During the same period patient was treated with ISONIAZID (200 Mg) (View Isoniazid Review and Isoniazid Label ), PYRAZINAMIDE (1 Mg) (View Pyrazinamide Review and Pyrazinamide Label ), ETHAMBUTOL HYDROCHLORIDE (ETHAMBUTOL) (500 Mg) (View Ethambutol Hydrochloride (ethambutol) Review and Ethambutol Hydrochloride (ethambutol) Label ).

4573063-0 | Blood Creatinine Increased, Haemodialysis
Patient was taking Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatinine increased, haemodialysis on Jan 26, 2005 from Additional patient health information: Male patient , 34 years of age, was diagnosed with tuberculosis gastrointestinal and. Rimactane dosage: 300 Mg, Oral. During the same period patient was treated with ISONIAZID (200 Mg) (View Isoniazid Review and Isoniazid Label ), PRYRAZINAMIDE (NGX) (PYRAZINAMIDE) (1 Mg) (View Pryrazinamide (ngx) (pyrazinamide) Review and Pryrazinamide (ngx) (pyrazinamide) Label ), ETHAMBUTOL HYDROCHLORIDE (500 Mg) (View Ethambutol Hydrochloride Review and Ethambutol Hydrochloride Label ), TACROLIMUS (TACROLIMUS) (View Tacrolimus (tacrolimus) Review and Tacrolimus (tacrolimus) Label ), DEOXYSPERGUALIN (View Deoxyspergualin Review and Deoxyspergualin Label ).

4562145-5 | Cytolytic Hepatitis, Hepatic Enzyme Increased, Hepatitis Cholestatic, Lymphopenia, Pruritus
Adverse event was reported on Jan 10, 2005 by a Male patient taking Rimactane (View Usage) (Dosage: 1800 Mg, Qd, Oral) . Location: , 87 years of age, Patient had the following side effects: cytolytic hepatitis, hepatic enzyme increased, hepatitis cholestatic, lymphopenia, pruritus. During the same period patient was treated with OMEPRAZOLE (40 Mg, Qd, Oral) (View Omeprazole Review and Omeprazole Label ), GLYBURIDE (2.5 Mg, Qd, Oral) (View Glyburide Review and Glyburide Label ), ACETAMINOPHEN (Qd, Oral) (View Acetaminophen Review and Acetaminophen Label ), OMIX (TAMSULOSIN HYDROCHLORIDE) (0.4 Mg, Qd, Oral) (View Omix (tamsulosin Hydrochloride) Review and Omix (tamsulosin Hydrochloride) Label ), CLAMOXYL /NET/ (AMOXICILLIN TRIHYDRATE) (Qd, Oral) (View Clamoxyl /net/ (amoxicillin Trihydrate) Review and Clamoxyl /net/ (amoxicillin Trihydrate) Label ). Patient was hospitalized.

4558995-1 | Anorexia, Skin Discolouration, Skin Nodule, Syncope
on Jan 12, 2005 Male patient from , 64 years of age, was treated with Rimactane (View Usage). After Rimactane was administered, patient had the following side effects: anorexia, skin discolouration, skin nodule, syncope. Rimactane dosage: . During the same period patient was treated with DAPSONE (View Dapsone Review and Dapsone Label ), LAMPRENE (5 Capsules/day) (View Lamprene Review and Lamprene Label ).

4554843-4 | Stevens-johnson Syndrome
on Nov 16, 2004 Female patient from , 74 years of age, was diagnosed with pulmonary tuberculosis and was treated with Rimactane (View Usage). Patient experienced the following unwanted or unexpected effects: stevens-johnson syndrome. Rimactane dosage: . During the same period patient was treated with ISONIAZID (View Isoniazid Review and Isoniazid Label ), ESANBUTOL (ETHAMBUTOL) (View Esanbutol (ethambutol) Review and Esanbutol (ethambutol) Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ).